Lilly obesity pill orforglipron is under FDA review with a decision expected in Q2 2025, aiming to compete with Novo Nordisk’s offerings.
Author: PharmaSignal News Desk
AbbVie invests $650 million in a dual-targeting immunotherapy from RemeGen, enhancing its oncology portfolio.
A senior BD execution signal from this month’s most instructive pharma deal.
PharmaSignal Take This week’s events signal a continued focus on M&A activity and regulatory approvals, with companies such as Lilly and BioMarin making strategic acquisitions, and Novo Nordisk and Cytokinetics gaining FDA approvals. These events stress test assumptions around execution readiness and regulatory optimism. In this week’s PharmaSignal Weekly Brief – Global Pharma Roundup, the dominant themes include M&A activity, regulatory approvals, and pipeline development. M&A and Strategic Deals Lilly’s $1.2B acquisition of Ventyx to target NLRP3 inflammasome signals a strategic move to expand its immunology portfolio. The deal structure and potential integration risks are worth noting. Read more →…
Insmed lung drug sales surpass expectations in Q1 2025, while J&J secures a US pricing deal.
Alveus obesity drug secures $160M to advance into Phase 2 testing, targeting amylin and GLP-1 pathways.
Lilly Ventyx acquisition for $1.2B focuses on NLRP3 inflammasome drugs, expanding Lilly’s immune drug pipeline.
GSK Ionis hepatitis B drug advances to global regulatory filings, aiming for functional cures in chronic infections.
FDA approval decisions in early 2026 include multiple national priority vouchers and a gene therapy, impacting the pharmaceutical landscape.
Alumis TYK2 psoriasis drug shows promise with Phase 3 results, doubling shares and competing with Takeda and Johnson & Johnson.